Blood cancers triggered by viral infections represent one of oncology's most cunning adversaries, as these malignancies have evolved sophisticated methods to hide from immune detection while maintaining viral persistence. This emerging battlefield could reshape how we approach cancer immunotherapy for millions of patients worldwide. The analysis identifies six key viral culprits—Epstein-Barr virus, HIV, HTLV-1, Kaposi's sarcoma-associated herpesvirus, and hepatitis B and C viruses—each employing distinct molecular strategies to transform healthy blood cells into malignant ones. These viruses don't simply cause cancer; they actively reprogram tumor cells to become invisible to immune surveillance systems that would normally eliminate them. The research reveals how viral proteins manipulate checkpoint pathways, suppress T-cell responses, and create immunosuppressive microenvironments that protect cancer cells from destruction. From a therapeutic perspective, this mechanistic understanding opens multiple intervention points previously unexplored in traditional oncology. The implications extend far beyond blood cancers, as these immune escape principles likely apply to other virus-associated malignancies affecting solid organs. However, the complexity of these viral-tumor interactions presents significant challenges for drug development, particularly in designing therapies that can simultaneously target viral replication and cancer cell survival without compromising overall immune function. The field remains in early stages, with most therapeutic approaches still experimental and requiring extensive validation in diverse patient populations before clinical implementation.